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Abstract
Background: Multidrug resistant (MDR) and extensively-drug resistant (XDR) tuberculosis (TB) are a serious threat to
the national TB control programs of developing countries, and the situation is further worsened by the human
immunodeficiency virus (HIV) pandemic. The literature regarding MDR/XDR-TB is, however, scanty from most parts
of India. We carried out this study to assess the prevalence of MDR/XDR-TB in new and previously treated cases of
pulmonary TB and in HIV seropositive and seronegative patients.
Methods: Sputum and blood specimens were obtained from 2100 patients suspected of pulmonary tuberculosis
and subjected to sputum microscopy and culture for TB, and HIV serology at our tertiary care centre in north India.
The culture positive Mycobacterium tuberculosis isolates were subjected to drug susceptibility testing (DST) for first
line anti-tuberculosis drugs, and the MDR isolates were further subjected to second line DST. Various parameters of
the patients’ were analyzed viz. clinical presentation, radiology, previous treatment history, demographic and
socioeconomic data and microbiology results.
Results: Of the 2100 patients, sputum specimens of 256 were smear positive for acid-fast bacilli (AFB), 271 (12.9%)
grew Mycobacterium spp., and M. tuberculosis was isolated in 219 (10.42%). Of the 219 patients infected with M.
tuberculosis, 20.1% (44/219) were found to be seropositive for HIV. Overall, MDR-TB was observed in 17.4% (39/219)
isolates. There were 121 newly diagnosed and 98 previously treated patients, of which MDR-TB was found to be
associated with 9.9% (12/121) and 27.6% (27/98) cases respectively. There was significantly higher association of
MDR-TB (12/44, 27.3%) with HIV seropositive patients as compared to HIV seronegative patients (27/175, 15.4%)
after controlling previous treatment status, age, and sex (odd’s ratio, 2.3 [95% CI, 1.000-5.350]; p-value, 0.05). No
XDR-TB was found among the MDR-TB isolates.
Conclusion: The present study demonstrated a high prevalence of drug resistance amongst pulmonary TB isolates
of M. tuberculosis from north India as compared to the WHO estimates for India in 2010, though this could possibly
be attributed to the clustering of more serious or referred cases at our tertiary care centre. The prevalence of
MDR-TB in HIV seropositive patients was significantly higher than seronegative individuals. The study emphasizes
the need to monitor the trends of drug resistance in TB in various populations in order to timely implement
appropriate interventions to curb the menace of MDR-TB.
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Background
At the 2007 World Health Assembly, WHO recognized
the importance of the situation and trends of multidrug
resistant (MDR) and extensively drug resistant (XDR)
strains of Mycobacterium tuberculosis as barriers to the
achievement of the WHO’s Global Plan’s objectives by
2015. Among the 8.8 million incident cases of Tubercu-
losis (TB), 3.6% are estimated to have MDR-TB per year
globally, and among the world’s 12.0 million prevalent
cases of TB, 650000 are estimated to be MDR-TB cases
[1]. Also, 58 countries have reported at least one case of
XDR-TB as of March 2010, and it is estimated that
about 5.4% of MDR-TB cases have XDR-TB.
According to WHO, nearly 50% of the world’s burden
of MDR-TB cases is in India and China [2]. The situ-
ation of TB is further threatened by the devastating
effect of human immunodeficiency virus (HIV) on tu-
berculosis susceptibility and the rapid expansion of
MDR-TB threaten to undermine the advances made by
tuberculosis management programs [3]. Tuberculosis is
one of the earliest opportunistic diseases to develop
amongst persons infected with HIV, and HIV infection
is the most powerful risk factor of progression of TB
from infection to disease with 21–34 times more
chances to develop the disease as compared to those
who are HIV-negative. Globally, just over one in ten of
the almost 9 million people who develop TB each year
are HIV-positive, equivalent to 1.1 million new TB cases
among people living with HIV [1].
MDR and XDR-TB are a serious threat to the national
tuberculosis control programs of developing countries.
The chances of patients with MDR-TB being cured are
low and they require significant expenditure of health
care resources. The level of drug resistance is said to
provide an epidemiological indicator to assess the
amount of transmission of resistant bacteria in the com-
munity, as the patients harbouring resistant bacilli re-
main infectious for a prolonged period and may be more
likely to infect others [4]. Hence there is a need to
strengthen the surveillance for drug-resistant TB to en-
sure continuous monitoring of the epidemiological pro-
file of MDR and XDR-TB. In India, it becomes difficult
to determine the exact magnitude of the problem of
drug resistance as majority of the laboratories providing
services for diagnosis of TB do not perform cultures of
TB and there are only a limited number of laboratories
capable of conducting quality assured first and second
line drug susceptibility testing (DST).
From India, though drug resistance in TB has fre-
quently been reported, most of the available information
is localized, sketchy or incomplete, and most studies
have used non-standardized methodologies to assess
drug resistance [5]. A large scale population based sur-
vey in the states of Gujarat and Maharashtra has
indicated multidrug resistance levels of <3% among new
TB cases and 12-18% among previously treated TB pa-
tients [6]. The literature regarding MDR/XDR-TB is
scanty in most of the other regions of the country. The
present study was hence planned to assess the preva-
lence of MDR/XDR-TB in patients with clinical suspi-
cion of pulmonary TB presenting to our tertiary care
centre which caters to a large population of patients
from several states of north India (Chandigarh, Punjab,
Haryana, Himachal Pradesh, Uttar Pradesh, Uttaranchal,
Jammu and Kashmir, and some parts of Rajasthan), with
the objective to evaluate the resistance patterns in new
and previously treated cases, and in HIV seropositive
and seronegative individuals. Many of these patients are
partially treated, and non compliance is a major factor
which may contribute to development of resistance to
anti-tuberculosis drugs.
Methods
The study was prospectively carried out from October,
2006 to February, 2010 for a span of 41 months. Sputum
and blood samples were obtained from 2100 patients
suspected of pulmonary TB attending the chest and
medical out patient’s departments (OPDs) of our tertiary
care centre, the Postgraduate Institute of Medical Educa-
tion and Research (PGIMER), Chandigarh, India. The
patients included had clinical signs and symptoms sug-
gestive of pulmonary TB (cough, fever, weight loss,
breathlessness, chest pain, hemoptysis), with/without
radiological evidences (exudation, infiltration, cavitation,
calcification, pleural effusion) and a family history of
pulmonary TB. All the tests were conducted at the
Mycobacteriology laboratory of PGIMER which is a
RNTCP (Revised National TB Control Programme) ap-
proved centre for tuberculosis culture and drug sensitiv-
ity testing accredited by Central TB Division, Ministry of
Health of the Government of India. A written informed
consent was taken from all the patients and the study
was approved by the Institute Ethics Committee of
PGIMER, Chandigarh.
The patients were categorized into seven age groups:
<11, 11–20, 21–30, 31–40, 41–50, 51–60, > 60 years of
age. The socio-economic status of the patients was
recorded based on their occupations; the lower socio-
economic class comprised of the agricultural workers,
manual labourers, household workers and unemployed
people, and the upper socio-economic class comprised
of salaried government or private professionals, and
businessmen.
A new case of TB was defined as a patient who has
never had treatment for TB or who has taken anti-TB
drugs for less than one month. Retreatment case of TB
were of three types: (i) a patient previously treated for
TB, who is started on a retreatment regimen after
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previous treatment has failed (treatment after failure);
(ii) a patient previously treated for TB who returns to
treatment having previously defaulted; and (iii) a patient
who was previously declared cured or treatment com-
pleted and is diagnosed with bacteriologically-positive
(sputum smear or culture) TB (relapse). A case of MDR-
TB was defined as TB that is resistant to two first-line
drugs: isoniazid and rifampicin [1]. XDR-TB was defined
as MDR-TB plus resistance to a fluoroquinolone and at
least one second-line injectable agent: amikacin, kana-
mycin and/or capreomycin [2].
Specimen collection and transport
Sputum
Two sputum samples from each patient were collected
in wide mouthed sterile capped containers and were
transported to the laboratory within an hour and
processed immediately. In case of delay, the samples
were stored at 4°C till processing.
Blood
From each patient 5–7 ml of blood was collected by
venipuncture. The serum was separated in the laboratory
and HIV screening was performed according to NACO
guidelines [7]. The serum was then stored at −20°C.
Sputum microscopy and culture
Sputum samples were subjected to Ziehl Neelsen’s acid
fast staining (ZN staining) to look for the presence of
acid fast bacilli (AFB). Samples were decontaminated by
N-Acetyl-L-Cysteine Sodium Hydroxide (NALC-NaOH)
method and cultured on LJ media, and identified
according to standard methods [8]. Inoculated cultures
were incubated at 37°C for 6 weeks and examined every
week to look for the presence of mycobacterial growth.
Any suspected growth on LJ medium was confirmed by
ZN staining for AFB, and the positive growths were sub-
cultured on fresh LJ media for further identification and
sensitivity.
Biochemical identification
Identification of mycobacteria isolated after primary cul-
ture on LJ medium was done by growth rate, colony
morphology, colour, niacin production, nitrate reduction,
catalase production at 68°C, and growth on LJ with PNB
(500 mg/ml).
Drug susceptibility testing (DST)
DST was carried out for first line anti-tuberculosis
drugs, namely rifampicin (40 μg/ml), isoniazid (1 μg/ml),
ethambutol (2 μg/ml) and streptomycin (4 μg/ml) using
the standard proportion method [9]. Briefly, growth
from positive LJ slopes was suspended in normal saline
and vortexed for 10–15 minutes. The suspension was
allowed to settle for 15–20 minutes and compared with
McFarland standard number one. Then, 1/100 and 1/
10000 dilutions of above suspension were prepared in
normal saline and used as inoculums. For each drug and
for each dilution, 100 μl of the inoculum was used to in-
oculate two drug-free and two drug-containing LJ
medium. Standard reference strain H37Rv was used as
control with each batch of sensitivity. The MDR isolates
were further screened for XDR-TB by performing sec-
ond line DST for ofloxacin (2 μg/ml), amikacin (1 μg/ml),
kanamycin (30 μg/ml), and capreomycin (40 μg/ml) in li-
quid culture by BACTEC MGIT 960 [10].
Statistical analysis
For demographic and DST data, frequencies, percent-
ages, means, medians, ranges, and confidence intervals
(CI) were calculated as appropriate. The differences in
groups were analysed by χ2 test. The association of
MDR-TB with HIV was analysed by multivariable re-
gression analysis. A two-sided p-value of less than 0.05
was considered as statistically significant. The data was
analyzed using the SPSS version 15.0 software.
Results
Study population
Sputum and blood specimens were obtained from a total
of 2100 patients clinically suspected of pulmonary tuber-
culosis prospectively enrolled in the study. There were
70.28% (1476) males and 29.71% (624) females. Patients
of all age groups were enrolled, and majority of the
patients i.e. 70.85% (1488/2100) were between 21 to
50 years of age, though there was no significant pre-
ponderance of TB in any specific age group (Table 1).
Microscopy and culture
Of the 2100 patients, sputum specimens from 256
(12.19%) were found positive for AFB, while the culture
grew Mycobacteria spp. in 271 (12.9%). Culture positivity
Table 1 Age wise distribution of M. tuberculosis and MDR-
TB isolates
Total Males Females
Age N MTB MDR N MTB MDR N MTB MDR
<11 29 1 0 18 0 0 11 1 0
11-20 219 24 8 137 16 4 82 8 4
21-30 501 52 10 338 34 6 163 18 4
31-40 568 71 15 403 51 11 165 20 4
41-50 419 39 4 307 28 3 112 11 1
51-60 228 23 1 170 18 1 58 5 0
>60 136 9 1 103 8 1 33 1 0
Total 2100 219 39 1476 155 26 624 64 13
MDR – multidrug resistant, MTB – M. tuberculosis, N – number.
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in smear positive cases was found to be 80.8% (207/256)
and culture positivity in smear negative cases was 3.4%
(64/1844). M. tuberculosis and non-tuberculous myco-
bacteria (NTM) grew from 10.42% (219) and 2.47% (52)
cases, respectively. The 52 NTM isolates (18 from HIV
positive and 34 from HIV seronegative) were not ana-
lyzed further. The 219M. tuberculosis isolates were
subjected to DST.
Among the 219 culture positive M. tuberculosis iso-
lates there were 121 newly diagnosed cases that had
never taken treatment for TB or had taken anti-TB treat-
ment for less than one month, while 98 patients gave a
history of previous anti-TB treatment more than one
month, of which 39 were treatment failures, 21 relapsed
after treatment, 13 defaulted during the therapy course,
and 25 patients did not provide sufficient history to be
categorized into any group.
Antimicrobial resistance
The drug resistance observed to any of the first line
drugs in new and previously treated patients was 26.4%
(95% CI, 19.4–35.4) and 46.9% (95% CI, 37.1–56.8) to
isoniazid, 9.9% (95% CI, 5.8–16.5) and 27.6% (95% CI,
18.7–36.4) to rifampicin, 14.9% (95% CI, 9.6–22.3) and
33.7% (95% CI, 24.3–43.0) to ethambutol, and 28.1%
(95% CI, 20.9–36.7) and 34.7% (95% CI, 25.3–44.1) to
streptomycin, respectively. The total mono-resistance in
new and previously treated patients was found to be
20.7% (95% CI, 13.4–27.9) and 32.6% (95% CI, 23.4–
41.9), respectively. Table 2 shows the resistance profile
of the M. tuberculosis isolates.
Overall, resistance to both isoniazid and rifampicin
(MDR) was observed in 17.8% (39/219; 95% CI, 12.7–
22.9) of the isolates. All the MDR strains were subjected
for susceptibility to second line anti-tubercular drugs,
however, no XDR strain was found in our study. Of the
39 MDR-TB isolates, the resistance to second line drugs
was 15.4% (6/39) to ofloxacin, 7.7% (3/39) to kanamycin,
and 2.5% (1/39) to amikacin, while no resistance to
capreomycin was observed. Among the new and previ-
ously treated cases, MDR-TB was found to be associated
with 9.9% (12/121; 95% CI, 4.6–15.2) and 27.6% (27/98;
Table 2 First line anti-tuberculosis drug resistance in new and previously treated patients
Total number of specimens = 2100 Previous anti-TB treatment status
New Previously treated Total
N % (95% CI) N % (95% CI) N % (95% CI)
Total DST results 121 5.8 98 4.7 219 10.4
I Any resistance to H 32 26.4 (19.4–35.4) 46 46.9 (37.1–56.8) 78 35.6 (29.3–42.0)
Any resistance to R 12 9.9 (5.8–16.5) 27 27.6 (18.7–36.4) 39 17.8 (12.7–22.9)
Any resistance to E 18 14.9 (9.6–22.3) 33 33.7 (24.3–43.0) 51 23.3 (17.7–28.9)
Any resistance to S 34 28.1 (20.9–36.7) 34 34.7 (25.3–44.1) 68 31.1 (24.9–37.2)
II Resistance to H only 10 8.3 (4.7–15.3) 14 14.3 (7.1–20.9) 24 10.9 (6.8–15.1)
Resistance to R only 0 0 (0–0) 0 0 (0–0) 0 0 (0–0)
Resistance to E only 0 0 (0–0) 7 7.1 (1.9–12.1) 7 3.1 (0.9–5.5)
Resistance to S only 15 12.4 (8.6–21.4) 11 11.2 (4.8–17.2) 26 11.9 (7.6–16.2)
Total mono-resistance 25 20.7 (13.4–27.9) 32 32.6 (23.4–41.9) 57 26.02 (20.2-31.9)
III H + R 1 0.8 (−0.8–2.8) 6 6.1 (1.3–10.7) 7 3.1 (0.9–5.5)
H + R + E 3 2.5 (0.04–6.04) 7 7.1 (1.9–12.1) 10 4.5 (1.8–7.3)
H + R + S 3 2.5 (0.04–6.04) 5 5.1 (0.7–9.3) 8 3.7 (1.2–6.2)
H + R + E + S 5 4.1 (1.1–8.9) 9 9.2 (3.3–14.7) 14 6.4 (3.2–9.6)
Total MDR 12 9.9 (4.6–15.2) 27 27.6 (18.7–36.4) 39 17.8 (12.7–22.9)
IV H + E 4 3.3 (0.5–7.5) 3 3.1 (−0.4–6.4) 7 3.1 (0.9–5.5)
H + S 5 4.1 (1.1–8.9) 2 2.04 (−0.8–4.8) 7 3.1 (0.9–5.5)
H + E + S 1 0.8 (0.8–2.8) 3 3.1 (−0.4–6.4) 4 1.8 (0.1–3.6)
R + E 0 0 (0–0) 0 0 (0–0) 0 0 (0–0)
R + S 0 0 (0–0) 0 0 (0–0) 0 0 (0–0)
R + E + S 0 0 (0–0) 0 0 (0–0) 0 0 (0–0)
E + S 5 4.1 (1.1–8.9) 4 4.1 (0.12–7.9) 9 4.1 (1.5–6.7)
Total poly-resistance other than MDR 15 12.4 (6.8–18.3) 12 12.2 (5.8–18.7) 27 12.3 (8.0–16.7)
CI – confidence interval, DST – drug susceptibility testing, E – ethambutol, H – isoniazid, R – rifampicin, S – streptomycin.
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95% CI, 18.7–36.4) cases, respectively. Of the 27 MDR
isolates obtained from previously treated patients, 20
were found in treatment failure (20/39), five in relapse
(5/21), and two in defaulter cases (2/13) (Table 3).
HIV co-infection
A total of 9.23% (194/2100) patients were found to be
seropositive for HIV. The percentage positivity among
males and females was 9.89% (146/1476) and 7.69% (48/
624) respectively. Of the 219M. tuberculosis isolates,
20.1% (44) and 79.9% (175) isolates were from HIV sero-
positive and seronegative patients, respectively. Among
the 44 HIV seropositive patients there were 12 (27.3%),
while in the 175 HIV seronegative patients there were 27
(15.4%) MDR isolates (Table 4). We applied multivari-
able regression analysis to see the association of MDR-
TB with HIV status after controlling the effects of
previous treatment status, age, and sex, and the associ-
ation was found to be significant with odd’s ratio of 2.3
(95% CI, 1.000-5.350; p-value, 0.05) (Table 5). Of the
remaining 32 (72.7%) strains from HIV positive patients,
18 (56.3%) isolates were susceptible to all the first line
drugs, while among the 148 HIV seronegative patients
which were not MDR, 80 (47.7%) isolates were suscep-
tible to all the first line drugs.
Socio-demographic data, clinical presentation, and
radiological picture of the TB cases
Among the 219M. tuberculosis isolates, 155 (70.7%) and
64 (29.3%) were obtained from males and female pa-
tients, respectively. The mean (median, range) age of the
patients was 36.6 years (35, 15–74), and 32.7 years (35,
4–75) for males and females respectively (p = 0.53). Of
the 219 patients, 66.9% were from a lower socioeco-
nomic background while 33.04% were of upper socioeco-
nomic status, however, the prevalence of MDR-TB was
found to be 19.5% and 23.7% in lower and upper socio-
economic groups, respectively, and the difference was
not statistically significant (p = 0.3373). Among the pa-
tients, 91.6% presented with cough (mean duration,
4.8 months; range, 2 days to 48 months), 76.2% with
fever (mean duration, 5.2 months; range, 7 days to 48 -
months), 73.2% with breathlessness, 68.8% with weight
loss, 57.5% with chest pain, and 31.5% presented with
hemoptysis. Radiology data was available for 49 patients,
of which there was consolidation in 34 patients, cavity in
5, collapse in 3, pleural effusion in 3, fibrosis in 2, mili-
tary shadows in 1, calcification in 1, and normal radi-
ology picture in 4 patients.
Discussion
The present study demonstrated a high prevalence of
drug resistance amongst pulmonary TB isolates of M.
tuberculosis from north India. In newly diagnosed cases
the resistance to any of the first line drugs was observed
to be 26.4% to isoniazid, 9.9% to rifampicin, 14.9% to
ethambutol, and 28.1% to streptomycin. This is in agree-
ment with reports from different parts of the country
showing high resistance to isoniazid (32.9%), rifampicin
(11.8%), and streptomycin (14.9%), but in contrast with a
few other studies reporting low resistance to the tune of
3.2%, 0.5%, and 4.8% to isoniazid, rifampicin, and
streptomycin respectively [5]. There was a high level of
Table 3 First line anti-tuberculosis drug resistance stratified by previous treatment history
Previously treated cases
Total Relapse Treatment failure Return after default Unknown
N N N N N
Total patients with DST 98 21 39 13 25
I Any resistance to H 46 9 22 4 11
III H + R 6 2 4 0 0
H + R + E 7 0 6 1 0
H + R + S 5 0 4 1 0
H + R + E + S 9 3 6 0 0
Total MDR among previously treated cases 27 5 20 2 0
Table 4 Anti-tuberculosis drug resistance stratified by
patient HIV status
DST results HIV status
Positive (N = 44) Negative (N = 175)
H + R Resistant to both 12 27
Not resistant to both 32 148
H Resistant 20 58
Sensitive 24 117
R Resistant 12 27
Sensitive 32 148
E Resistant 7 45
Sensitive 37 130
S Resistant 13 55
Sensitive 31 120
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drug resistance in previously treated cases for any of the
first line drugs i.e. 46.9% to isoniazid, 27.6% to rifampi-
cin, 33.7% to ethambutol, and 34.7% to streptomycin.
Other studies from India have also shown high resist-
ance to isoniazid (47–87.1%) and rifampicin (12.6-80.6%)
in previously treated cases; however, the number of iso-
lates in most of the studies was small so the high resist-
ance reported cannot be extrapolated to the whole
country [5].
There were 39 cases of MDR-TB found in the study
with an overall prevalence of 17.8% (39/219). In new
cases a prevalence of 9.9% MDR-TB was observed which
is higher than the WHO estimated prevalence of 2.1%
cases of MDR-TB among the notified newly diagnosed
pulmonary TB cases in India in 2010. However, the re-
ports of prevalence of MDR-TB in newly diagnosed
cases vary from 0.6 to 24% from different regions of the
country [11-13]. Similarly, among the previously treated
group multidrug resistance was seen to be 27.6%, which
is higher than the WHO estimate of 15% MDR-TB in
notified retreatment cases in India in 2010, though other
studies from different regions of the country report
MDR-TB varying from 11.8 to 47.1% [14-17]. The data
of MDR-TB from other regions of the world ranges from
2.1%, 4.9%, and 12%, in newly diagnosed cases to 12%,
23%, and 37% in re-treatment cases in the Region of the
Americas, Western Pacific Region, and European Region
respectively [1]. The wide range of resistance data from
different parts of India indicates the lack of uniform sur-
veillance methodologies across the country. Also, the
sample size in most of the studies is small and do not re-
flect a wholesome picture of the resistance data. On the
other hand, this difference in the resistance patterns may
be true to some extent, considering the wide geograph-
ical and administrative divisions of the country reflecting
the gaps in implementation of the national TB control
programs; although this needs to be studied in large
multi-centric surveillance studies using uniform meth-
odologies to obtain the drug resistance data. The high
prevalence in our study could be attributed to the fact
that it was carried out at a tertiary care hospital where
patients are being referred from different parts of north
India. Surprisingly, we did not find any isolate which
was XDR-TB though XDR-TB has been reported from
India and other parts of the world [18-22].
Of the total 2100 cases, there was a seropositivity of
9.23% for HIV, while among the 219 patients with TB
there were 20.1% seropositive cases. In our study, a
higher prevalence of HIV in TB patients was found as
compared to the WHO estimate of a prevalence of 9%
of HIV in TB patients in India for 2010, which may pos-
sibly be due to clustering of referred cases at our tertiary
care hospital. However, similar to our findings a few
studies from other parts of the country have shown
higher seroprevalence of HIV in TB approaching to 17%
and 20.39% from Chennai and Pune respectively [23,24].
There was a significantly higher number of MDR M.
tuberculosis isolates in the HIV seropositive group i.e.
27.3%, as compared to 15.4% in HIV seronegative group
with an odd’s ratio of 2.3 (95% CI, 1.000-5.350; p value,
0.05).
In the present study, a majority of the patients with
TB were from a lower socioeconomic background
(66.9%), however the prevalence of MDR-TB in these pa-
tients was found to be 19.5% which was not significantly
different from the prevalence of 23.7% among the pa-
tients of upper socioeconomic status. This indicates that
although TB is more common in poor patients, yet pov-
erty was not a determining factor for the occurrence of
MDR-TB, although the sample size was not sufficient to
give this observation a statistical significance. In a recent
study conducted in South India, Gupta et al. observed a
significantly higher prevalence of pulmonary TB in
labourers, followed by white-collar workers, retired and
unemployed, household workers and students, however,
they have not looked into drug resistance patterns in
these patients [25]. The increased incidence of pulmon-
ary TB among socio-economically lower classes can be
attributed to lower education level and poverty [26,27],
although the true prevalence of TB in poor sections of
Table 5 Multivariable regression model showing association of MDR-TB with HIV status after controlling the effects of
age, sex, and previous treatment status
Parameter estimates
MDR(a) B Std. Error Wald df p-value Odd’s Ratio 95% CI for Odd’s Ratio
+ VE Intercept −1.777 0.876 4.118 1 0.042 - -
Sex 0.284 0.415 0.467 1 0.494 1.328 0.589-2.997
Treatment 1.380 0.397 12.066 1 0.001 3.976 1.825-8.664
Age −0.030 0.015 3.879 1 0.049 0.971 0.942-1.000
[C_HIV = 1] 0.839 0.428 3.842 1 0.050 2.313 1.000-5.350
[C_HIV = 2] 0(b) - 0 - - -
a – The reference category is: - VE, b – This parameter is set to zero because it is redundant, CI – confidence interval, df – degree of freedom.
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the society may be higher than estimated because such
patients have limited access to hospital medical services
and a high mortality rate [25].
Conclusion
In conclusion, in this study we demonstrate a high
prevalence of drug resistance amongst pulmonary TB
isolates of M. tuberculosis from northern India. There
was a high prevalence of MDR-TB in both new and pre-
viously treated patients as compared to the WHO esti-
mated prevalence of MDR-TB in India in 2010, however,
we did not find any XDR-TB isolate. We also observed a
high prevalence of HIV among the TB patients and sig-
nificant association of MDR-TB with HIV seropositive
patients as compared to seronegative patients. Although
TB was found to be more common in patients with poor
socioeconomic background, yet there was no significant
difference in the distribution of MDR-TB in different so-
cial strata.
The data from the present study should be extrapo-
lated with certain limitations given the diverse popula-
tion from which these estimates were made. The
enrolled patients presented to our tertiary care centre
from several states of north India, and many of our pa-
tients are partially treated previously, before being re-
ferred to our centre to seek additional care. This may
have resulted in higher proportions of patients with
MDR-TB at the time they were initially diagnosed at our
centre, as patients with less resistant disease may not
have needed to seek additional care. The higher preva-
lence of HIV in our TB patients compared to the WHO
estimates for India may again possibly be due to cluster-
ing of referred cases at our tertiary care centre.
Overall, these findings emphasize the importance of
continuing the systematic surveillance of M. tuberculosis
isolates to monitor the trends of drug resistance in dif-
ferent patient categories as well as its association with
HIV across the country to timely modify and strengthen
the national programs in order to prevent the emergence
of MDR-TB strains and avert the threat of XDR-TB.
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